Press releases

Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)

Regulatory

September 23, 2022

Stockholm, Sweden – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held on Friday, 23 September 2022. At the Extraordinary General Meeting, the following principal resolution wa...

Read more

Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC

Regulatory

September 23, 2022

STOCKHOLM — September 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, toda...

Read more

Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published

September 20, 2022

STOCKHOLM — September 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, toda...

Read more

Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma

September 7, 2022

STOCKHOLM — September 7, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today...

Read more

Extraordinary General Meeting in Oncopeptides AB (publ)

Regulatory

August 30, 2022

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extra...

Read more

European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

Regulatory

August 18, 2022

STOCKHOLM — August 18, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today a...

Read more

Oncopeptides publishes Q2 report 2022

Regulatory

August 11, 2022

STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today p...

Read more

Number of shares and votes in Oncopeptides

Regulatory

July 29, 2022

Stockholm, Sweden — July 29, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, t...

Read more

FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides’ Pepaxto

July 20, 2022

STOCKHOLM — July 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ann...

Read more

Oncopeptides has carried out a directed share issue of approximately SEK 435.6 million (approximately USD 41.1 million)

Regulatory

July 14, 2022

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW...

Read more

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Regulatory

June 28, 2022

Stockholm, Sweden – June 28, 2022 – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Tuesday, 28 June 2022. At the Annual General Meeting, the following principal resolutions we...

Read more

CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU for patients with triple class refractory multiple myeloma

Regulatory

June 23, 2022

STOCKHOLM — June 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ann...

Read more

Annual General Meeting in Oncopeptides AB (publ)

May 25, 2022

STOCKHOLM — May 25, 2022 — The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given...

Read more

Oncopeptides publishes Q1 report 2022

Regulatory

May 4, 2022

STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publi...

Read more

Invitation to presentation of Q1 report

April 27, 2022

STOCKHOLM — April 27, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...

Read more

Oncopeptides publishes the 2021 Annual Report

Regulatory

April 21, 2022

STOCKHOLM — April 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...

Read more

Number of shares and votes in Oncopeptides

Regulatory

March 31, 2022

STOCKHOLM — March 31, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...

Read more

Oncopeptides publishes year-end report 2021

Regulatory

February 17, 2022

STOCKHOLM — February 17, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today publ...

Read more

Invitation to presentation of 2021 year-end results

February 14, 2022

STOCKHOLM — February 14, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish i...

Read more

Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US – no intent to market in the US at this time

Regulatory

January 21, 2022

STOCKHOLM — January 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...

Read more

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

January 13, 2022

STOCKHOLM — January 13, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...

Read more

Oncopeptides announces year-end cash 2021

Regulatory

January 5, 2022

STOCKHOLM — January 5, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today a...

Read more